Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
anyone think this gets good news after hours tonite,,are they a buyout target??
Had the same thing on TDA.
how could it be?
When you have so solid ownership(87%) you don't need to think twice.
a lot of new stuckees after this collapse.
KBIO still the most solid from all other biotech companies mentioned recently
agreements with Sanofi and Novartis..."Since our inception, we have financed our operations primarily through proceeds from the public offerings of our common stock, private placements of our preferred stock, debt financings, interest income earned on cash, and cash equivalents, and marketable securities, borrowings against lines of credit, and receipts from agreements with Sanofi and Novartis. At June 30, 2015, we had cash and cash equivalents and investments of $23.0 million"
Cap is why below it's Cash
Development Program Updates
KB004 Immuno-oncology Program
KB004, the company's monoclonal antibody (mAb) targeting EphA3, is currently in clinical development in the phase 2 expansion portion of an open-label Phase 1/2 study in hematologic malignancies. The Phase 2 portion of the study is currently enrolling two cohorts of up to 20 patients each at the 250mg dose level selected as a result of the Phase 1 dose escalation portion of the study. One cohort consists of patients with myelodysplastic syndrome (MDS), and a second cohort consists of patients with myelofibrosis (MF). Patients in both cohorts must be relapsed-refractory to standard-of-care treatment, and pre-screened to ensure tumor EphA3 expression. As of August 1, 2015, the phase 2 expansion portion of the study has enrolled a total of 8 patients in the MDS cohort and 6 patients in the MF cohort. Based on current enrollment rates, and with several additional clinical sites expected to commence enrollment in the coming months, the company expects enrollment to continue to accelerate. The drug continues to be well tolerated with the most commonly reported side effects being infusion reactions.
KB003 Oncology Program
In July, KaloBios announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug (IND) application for KB003, an anti-GM-CSF mAb, testing in patients with chronic myelomonocytic leukemia (CMML), an orphan oncology indication. As a result, KaloBios is initiating an open-label Phase I study designed to evaluate the safety, pharmacokinetics and clinical activity of KB003 in previously treated CMML patients. The study will consist of an accelerated dose-escalation component starting at 200 mg and escalating up to 600 mg, followed by a cohort expansion of up to 13 additional patients to explore clinical activity at the selected dose level. Site initiation activities are underway, and the company anticipates that enrollment will begin later this year.
"We have made excellent progress in 2015 in strengthening our oncology focus at KaloBios," said Herb Cross, KaloBios' Chief Financial Officer and Interim Chief Executive Officer. "We continue to work to expand our portfolio of oncology programs in clinical development, most notably with the addition of a third oncology indication as a result of the July FDA clearance of our IND for KB003 in CMML. We continue to enroll patients in the KB004 Phase 2 program in MDS and MF, as well as evaluating additional potential oncology indications for KB004 including solid tumors where EphA3 is expressed. With several oncology indications either in development or moving into the clinic, and other potential indications under evaluation, we continue to be excited about the potential of our assets."
sweet,mm just washed out cheap stops,,poor fools who set em cheap lol
if the markets will not collapse again. dow -312.54
I'm ready for it...hopefully see $5 again before the day's up.
2nd leg run up to bat,,lunch over,im still hungry$$$$
I will send you a pm
Which ones do you think are going to run
could be just a bunch of shares trading hands, I moved on and took my profits, looking for the next one....I have a couple that I think will run nicely soon.
agree Mark.Thoughts relating O/S count after past 2 days?...
Nice run here huh Ash? Congrats as we were very early on it....
WE COULD DREAM OF $15 NEXT WEEK IF NO SHORT-SELLING AND BIG TRADERS HOLD.
Yep ash has been on a roll - http://www.reuters.com/article/2007/05/22/simons-hedge-idUSN2135575220070522 esp with Renaissance holding it
KBIO is not available for short selling at this time. For further assistance, please contact your branch.
SCOTTRADE
$6.88 is keytoblu skie$$$$ myop
it seems the o/s is not longer 4m after past 2 days volume.but have not seen any form 4 yet.
TY.im buying only and only solid nasdaq companies backup with solid DD.
that's why i alerted KBIO and SGNL:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116670051&txt2find=KBIO|SGNL
thru $5,,then gonna xplode $12+ myop
INTERESTING RUN FOR KBIO...IMO CHART SAYS 5+ COMETH.
NICE JOB ASH FROM UNDER $2 TO $4.72
CONGRAT$$$
took profits here.it's solid due to cash/share ratio.will be waiting for news here.
$KBIO chart - very sweet follow through today - the close above the 50 day simple moving average yesterday was the bull signal - the 100 DMA is the key level to turn into support - RSI & Fast STO are now in the overbought/power zone - this chart is from yesterday -
September 3, 2015 at 9:34 am #9362 EDIT | CLOSE | STICK (TO FRONT) | MERGE | TRASH | SPAM | REPLY | QUOTE
Ospreyeye
$KBIO Chart – bullish move today above the 50 DMA @ 2.60 on large volume – key level to turn into support – the 100 DMA @ 3.44 is the key resistance level to break – a close above puts the 200 DMA @ 5.44 on deck –
wow..bought to get in on this
RUN BABY RUN!!
no new but volume spike and pps movement. hmmm something will be disclosed
KBIO if good news hit it's a possibility,on no news the near this still could be trading 3-4.
$12+ breaks us big $23+ myop
Almost 4 pre.
Up 44%..could see AH action
everything could happen here,meanwhile it's moving due to the solid balance sheet and Cash/share ratio. i hope good news will follow as well at some point
dilution here
pump is over
Lunchy dip...than Rip to $4 eod
OK, yeah, let's do that.
$4-$5 easy
Hi ash.Long time no seen on the same-ticker...eom
$4 very possible today.
Maybe see $5?
Followers
|
327
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
42787
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |